
|Articles|June 17, 2009
June TOC
June TOC
Advertisement
Advertisement
Related to this article

Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.

DISCO Pharmaceuticals gets $40M upfront from AbbVie and could earn up to $2.5B in milestones to develop AND-gated bispecifics for solid tumors.

As specialty drug complexity grows, agentic technology puts the right access, adherence, and affordability resources at the provider’s fingertips at prescribing.

J&J’s separations of Kenvue and DePuy Synthes test whether Innovative Medicine and MedTech create more value together than apart.

Dr. Joe Geraci of NetraMark explains how AI analysis of clinical trial data can uncover hidden responder subgroups, separate true drug responders from placebo responders, and potentially rescue drug assets that appeared to fail in Phase II.

Parexel’s Stacy Hurt explains why AI can speed up clinical research but can’t replace the lived experience of patients.

The month's biggest moves — from Pfizer and Blackstone's obesity co-funding agreement to Lilly's $3.5B Pennsylvania groundbreaking — answered in plain language.
Advertisement
Advertisement
Trending on PharmExec
1
Pfizer, Verismo Strike Licensing Deals to Push CAR T Manufacturing In Vivo
2
Keeping Human Expertise at the Center of AI
3
Your Questions Answered: GLP-1 Deals, FDA Approvals, and Manufacturing Buildout
4
Johnson & Johnson's Strategic Shift: Why Diversification Is Giving Way to Focus
5

